← All trials
NCT05743179
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2022
- Primary completion
- May 31, 2025
- Completion date
- Jun 30, 2025
- First posted
- Feb 24, 2023
- Last posted
- Feb 24, 2023
- Enrollment
- 2692
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The University of Hong KongLead sponsor
- Chinese University of Hong KongCollaborator
- City University of Hong KongCollaborator
- The University of Hong KongCollaborator
- The University of Hong KongOverall official - principal investigator
- Caritas Medical CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.